A Comprehensive Scientific Analysis Showing That Adequate Vitamin D Levels Reduce Cancer Risk

In 2012, there were 14 million new cancer cases worldwide and 8.2 million people died from cancer. Over the next 20 years, annual new cancer cases are projected to rise to 22 million. In America in 2016, more than 1.68 million new cancer diagnoses and approximately 600,000 cancer deaths are expected. In America in 2010, a total of 125 billion dollars was spent on cancer treatment, and in 2020 this amount is expected to exceed 150 billion dollars. The priority measure is to reverse or slow the rising trend in cancer rates, treatment burden, mortality and associated costs.
Approximately 35 years ago, high colon cancer mortality was observed in high-latitude regions with little sunlight, leading to the first suggestion of a relationship between vitamin D and cancer. Since then, studies have observed an inverse relationship between vitamin D [25(OH)D] and the risk of many cancers, including breast, prostate and colorectal cancer. One study found a 60% reduction in cancers other than skin cancer in women receiving vitamin D and calcium treatment compared with those not receiving it.
This study was conducted in women aged 55 and over to measure more clearly the relationship between 25(OH)D and the risk of cancers other than skin cancer. In doing so, the widest measurement range of 25(OH)D was evaluated compared with measures in previous studies. Using results from two previous separate studies, the research used the first study’s 30 ng/ml 25(OH)D measure and, from another larger study with volunteers from 52 countries, the 48 ng/ml 25(OH)D measure.
The first study included women whose cancer status at the research date or during the preceding 10 years was unknown, aged 55 and over, totaling 1169 women, who received vitamin D and calcium supplementation. Participants were divided into three groups and followed for an average of 4 years. The first group received calcium (either 1400 mg calcium citrate daily or 1500 mg calcium carbonate daily), and the second received calcium and vitamin D (calcium in the quantities mentioned and 1000 IU vitamin D daily). The third remained the control group (calcium and vitamin D placebos).
The other larger study likewise included women whose cancer status at participation or in the preceding 10 years was unknown, but who had completed at least 2 health assessments or 25(OH)D measurements, aged 55 and over, totaling 1135 women. Participants completed health questionnaires and blood tests from January 2009 - December 2014 at 6-month intervals. They reported cancer diagnosis dates and types, calcium supplement consumption, smoking and body mass index (weight and height calculations). In both studies, cancer incidence over an average of 3.9 years was compared according to the 25(OH)D measure.
Because the second study was larger, its statistical data are stronger. This provides more information about the wide measurement range of 25(OH)D than the other study. Serum 25(OH)D was assessed as an independent variable, examining its effects alone and the individualized dose response.
The studies found that, a blood vitamin D level of 20 ng/ml or above is necessary for bone health, and blood vitamin D levels of 40 ng/ml or above reduced cancer risk in women by 67% . Analyses show that cancer incidence decreases as vitamin D levels increase. The results suggest measuring blood vitamin D levels for both bone health and cancer risk and, particularly if vitamin D is below 20 ng/ml, taking a vitamin D supplement according to your doctor’s plan.
Reversing the current worldwide upward trend in cancer incidence is not possible solely through improvements in early diagnosis or treatment opportunities. Cancer prevention should be our primary priority, and this analysis suggests that improving vitamin D levels may be an important cancer prevention tool.
Sources
Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with >65% Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study.
PLOS ONE. April 6, 2016https://dx.doi.org/10.1371/journal.pone.0152441
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.